RECRUITING
I'm interested ...!!
Mechanisms for Activation of Beige Adipose Tissue in Humans
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
Conditions:
🦠 PreDiabetes
🗓️ Study Start (Actual) 7 December 2020
🗓️ Primary Completion (Estimated) 31 December 2024
✅ Study Completion (Estimated) 31 December 2024
👥 Enrollment (Estimated) 65
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE2
Locations:
📍 Lexington, Kentucky, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * BMI 27-45
    • * prediabetes (A1c 5.7-6.4)
    • * impaired fasting glucose or impaired glucose tolerance

    Exclusion Criteria:

    • * diabetes
    • * chronic use of anti-diabetic medication
    • * acute or chronic inflammatory condition
    • * unstable medical condition
    • * cancer
    • * renal insufficiency
    • * any contraindication for Mirabegron
    • * BMI \>45
Ages Eligible for Study: 35 Years to 65 Years (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 7 December 2020
  • First Submitted that Met QC Criteria 7 December 2020
  • First Posted 14 December 2020

Study Record Updates

  • Last Update Submitted that Met QC Criteria 7 December 2023
  • Last Update Posted 11 December 2023
  • Last Verified December 2023
I'm interested ...!!